Canada · Delayed Price · Currency is CAD Cannara Biotech Statistics
Total Valuation
Cannara Biotech has a market cap or net worth of CAD 174.84 million. The enterprise value is 187.17 million.
| Market Cap | 174.84M |
| Enterprise Value | 187.17M |
Important Dates
The last earnings date was Tuesday, April 14, 2026.
| Earnings Date | Apr 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cannara Biotech has 98.78 million shares outstanding. The number of shares has increased by 3.00% in one year.
| Current Share Class | 98.78M |
| Shares Outstanding | 98.78M |
| Shares Change (YoY) | +3.00% |
| Shares Change (QoQ) | +2.33% |
| Owned by Insiders (%) | 3.92% |
| Owned by Institutions (%) | 0.22% |
| Float | 45.50M |
Valuation Ratios
The trailing PE ratio is 16.28 and the forward PE ratio is 11.42.
| PE Ratio | 16.28 |
| Forward PE | 11.42 |
| PS Ratio | 1.55 |
| PB Ratio | 1.45 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | 10.85 |
| P/OCF Ratio | 6.33 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.73, with an EV/FCF ratio of 11.62.
| EV / Earnings | 18.43 |
| EV / Sales | 1.66 |
| EV / EBITDA | 7.73 |
| EV / EBIT | 10.50 |
| EV / FCF | 11.62 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.28.
| Current Ratio | 3.06 |
| Quick Ratio | 1.15 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.41 |
| Debt / FCF | 2.12 |
| Interest Coverage | 6.33 |
Financial Efficiency
Return on equity (ROE) is 9.48% and return on invested capital (ROIC) is 9.10%.
| Return on Equity (ROE) | 9.48% |
| Return on Assets (ROA) | 6.49% |
| Return on Invested Capital (ROIC) | 9.10% |
| Return on Capital Employed (ROCE) | 11.73% |
| Weighted Average Cost of Capital (WACC) | 6.21% |
| Revenue Per Employee | 250,033 |
| Profits Per Employee | 22,473 |
| Employee Count | 452 |
| Asset Turnover | 0.66 |
| Inventory Turnover | 1.31 |
Taxes
In the past 12 months, Cannara Biotech has paid 5.04 million in taxes.
| Income Tax | 5.04M |
| Effective Tax Rate | 33.15% |
Stock Price Statistics
The stock price has increased by +25.71% in the last 52 weeks. The beta is 0.38, so Cannara Biotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +25.71% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 1.79 |
| Relative Strength Index (RSI) | 43.54 |
| Average Volume (20 Days) | 61,053 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cannara Biotech had revenue of CAD 113.01 million and earned 10.16 million in profits. Earnings per share was 0.11.
| Revenue | 113.01M |
| Gross Profit | 48.00M |
| Operating Income | 17.83M |
| Pretax Income | 15.19M |
| Net Income | 10.16M |
| EBITDA | 23.94M |
| EBIT | 17.83M |
| Earnings Per Share (EPS) | 0.11 |
Balance Sheet
The company has 21.90 million in cash and 34.22 million in debt, with a net cash position of -12.32 million or -0.12 per share.
| Cash & Cash Equivalents | 21.90M |
| Total Debt | 34.22M |
| Net Cash | -12.32M |
| Net Cash Per Share | -0.12 |
| Equity (Book Value) | 120.21M |
| Book Value Per Share | 1.22 |
| Working Capital | 61.34M |
Cash Flow
In the last 12 months, operating cash flow was 27.64 million and capital expenditures -11.53 million, giving a free cash flow of 16.11 million.
| Operating Cash Flow | 27.64M |
| Capital Expenditures | -11.53M |
| Depreciation & Amortization | 6.11M |
| Net Borrowing | -3.63M |
| Free Cash Flow | 16.11M |
| FCF Per Share | 0.16 |
Margins
Gross margin is 42.47%, with operating and profit margins of 15.78% and 8.99%.
| Gross Margin | 42.47% |
| Operating Margin | 15.78% |
| Pretax Margin | 13.44% |
| Profit Margin | 8.99% |
| EBITDA Margin | 21.18% |
| EBIT Margin | 15.78% |
| FCF Margin | 14.26% |
Dividends & Yields
Cannara Biotech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.00% |
| Shareholder Yield | -3.00% |
| Earnings Yield | 5.81% |
| FCF Yield | 9.22% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Feb 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Cannara Biotech has an Altman Z-Score of 2.84 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.84 |
| Piotroski F-Score | 8 |